CN112469474A - 出血和centhaquin引起的复苏后内皮素受体的变化 - Google Patents

出血和centhaquin引起的复苏后内皮素受体的变化 Download PDF

Info

Publication number
CN112469474A
CN112469474A CN201980038669.0A CN201980038669A CN112469474A CN 112469474 A CN112469474 A CN 112469474A CN 201980038669 A CN201980038669 A CN 201980038669A CN 112469474 A CN112469474 A CN 112469474A
Authority
CN
China
Prior art keywords
centhaquin
renal
bleeding
blood
receptor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201980038669.0A
Other languages
English (en)
Chinese (zh)
Inventor
A·古拉提
M·拉夫哈尔
B·卡蒂娅
A·K·辛格
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Pharmazz Inc
Midwestern University Glendale
Original Assignee
Pharmazz Inc
Midwestern University Glendale
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmazz Inc, Midwestern University Glendale filed Critical Pharmazz Inc
Publication of CN112469474A publication Critical patent/CN112469474A/zh
Pending legal-status Critical Current

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2285—Endothelin, vasoactive intestinal contractor [VIC]
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Zoology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Endocrinology (AREA)
  • Vascular Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN201980038669.0A 2018-05-03 2019-05-03 出血和centhaquin引起的复苏后内皮素受体的变化 Pending CN112469474A (zh)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862666675P 2018-05-03 2018-05-03
US62/666675 2018-05-03
IN201841019588 2018-05-25
IN201841019588 2018-05-25
PCT/US2019/030652 WO2019213558A1 (en) 2018-05-03 2019-05-03 Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin

Publications (1)

Publication Number Publication Date
CN112469474A true CN112469474A (zh) 2021-03-09

Family

ID=68386694

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201980038669.0A Pending CN112469474A (zh) 2018-05-03 2019-05-03 出血和centhaquin引起的复苏后内皮素受体的变化

Country Status (9)

Country Link
US (1) US20210169978A1 (https=)
EP (2) EP3813942B1 (https=)
JP (1) JP7458032B2 (https=)
CN (1) CN112469474A (https=)
AU (1) AU2019262612B2 (https=)
BR (1) BR112020022395A2 (https=)
ES (1) ES2978951T3 (https=)
PL (1) PL3813942T3 (https=)
WO (1) WO2019213558A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2010241564B2 (en) 2009-04-30 2014-07-31 Midwestern University Novel therapeutic treatments using centhaquin
JP2024517334A (ja) * 2021-05-11 2024-04-19 ファーマズ，インコーポレイテッド コロナウイルス疾患（ｃｏｖｉｄ－１９）における急性呼吸窮迫症候群（ａｒｄｓ）の治療のための医薬組成物及び方法
US20240207356A1 (en) * 2022-12-26 2024-06-27 Pharmazz, Inc. Composition and method for wound healing and repair of damaged nerves
US20240382461A1 (en) * 2023-05-15 2024-11-21 Pharmazz, Inc. Pharmaceutical composition and method for prevention and treatment of hearing loss
IN202411028038A (https=) * 2024-04-04 2025-05-23

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209433A1 (en) * 2005-12-01 2010-08-19 B.R.A.H.M.S Aktiengesellschaft Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
CN103989682A (zh) * 2009-04-30 2014-08-20 美国中西部大学 使用centhaquin的新治疗法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH0597891A (ja) * 1991-04-24 1993-04-20 Banyu Pharmaceut Co Ltd 血管弛緩ペプチド類
CA2578709C (en) * 2004-06-17 2010-06-15 Virun, Inc. Compositions comprising a mucoadhesive protein and an active principle for mucosal delivery of said agents
JP2009506119A (ja) * 2005-08-31 2009-02-12 ユニバーシティ オブ テネシー リサーチ ファウンデーション 選択的アンドロゲン受容体モジュレーターを用いる腎疾患、熱傷、創傷および脊髄損傷の処置
US20080242687A1 (en) * 2007-04-02 2008-10-02 Auspex Pharmaceuticals, Inc. Substituted pyrimidines
AU2008237062A1 (en) 2007-04-10 2008-10-16 Auspex Pharmaceuticals, Inc. Substituted deuterium enriched thiophenes for the treatment of hypertension
EP2545920A1 (en) 2007-08-22 2013-01-16 Abbott GmbH & Co. KG Therapy for complications of diabetes
US20130296331A1 (en) 2010-11-26 2013-11-07 Technion Research And Development Foundation Ltd. Compositions and methods for ameliorating renal dysfunction induced by renal hypoperfusion or acute kidney injury
BR112015004643A2 (pt) 2012-08-31 2017-07-04 Univ Midwestern métodos e composições para ressucitação hipotensiva
AU2014287427B2 (en) 2013-07-08 2019-11-21 Midwestern University Compositions and methods for treating neuropsychiatric disorders using an endothelin-B receptor agonist

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100209433A1 (en) * 2005-12-01 2010-08-19 B.R.A.H.M.S Aktiengesellschaft Methods for the diagnosis and for the treatment of critically ill patients with endothelin, endothelin agonists and adrenomedullin antagonists
CN103989682A (zh) * 2009-04-30 2014-08-20 美国中西部大学 使用centhaquin的新治疗法

Non-Patent Citations (3)

* Cited by examiner, † Cited by third party
Title
ANIL GULATI ET AL.: "Endothelin Receptor Alteration Following Hemorrhagic Shock and Resuscitation by Centhaquin", vol. 236, pages 1 *
CARMEN DE MIGUEL ET AL.: "Endothelin receptor-specific control of endoplasmic reticulum stress and apoptosis in the kidney", vol. 7, pages 1 - 13 *
王健仰主编: "《内科学速记》", 中国医药科技出版社, pages: 326 *

Also Published As

Publication number Publication date
EP3813942A1 (en) 2021-05-05
JP2021523125A (ja) 2021-09-02
EP3813942A4 (en) 2022-01-19
AU2019262612B2 (en) 2025-04-03
AU2019262612A1 (en) 2020-11-26
WO2019213558A1 (en) 2019-11-07
CA3099128A1 (en) 2019-11-07
US20210169978A1 (en) 2021-06-10
PL3813942T3 (pl) 2024-07-22
JP7458032B2 (ja) 2024-03-29
ES2978951T3 (es) 2024-09-23
EP3813942B1 (en) 2024-04-17
BR112020022395A2 (pt) 2021-04-13
EP4364811A2 (en) 2024-05-08
EP4364811A3 (en) 2024-07-10

Similar Documents

Publication Publication Date Title
CN112469474A (zh) 出血和centhaquin引起的复苏后内皮素受体的变化
Zhao et al. Wnt/β-catenin signaling mediates both heart and kidney injury in type 2 cardiorenal syndrome
US20200375953A1 (en) Methods of Treating Hepatorenal Syndrome and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
Zhong et al. Berberine inhibits NLRP3 inflammasome activation by regulating mTOR/mtROS axis to alleviate diabetic cardiomyopathy
Lin et al. A simplified herbal decoction attenuates myocardial infarction by regulating macrophage metabolic reprogramming and phenotypic differentiation via modulation of the HIF-1α/PDK1 axis
Kuma et al. Inhibition of urea transporter ameliorates uremic cardiomyopathy in chronic kidney disease
Wang et al. Preventive effect of LCZ696 on hypoxic pulmonary hypertension in rats via regulating the PI3K/AKT signaling pathway
Jiang et al. Thiazole isomers as potential ALK5 inhibitors alleviate P2X7R-mediated inflammation during liver fibrosis
Monogiou Belik et al. The Flt3-inhibitor quizartinib augments apoptosis and promotes maladaptive remodeling after myocardial infarction in mice
JP2025170421A (ja) 全身性硬化症の予防または治療用薬学的組成物
CN106692150A (zh) 尼达尼布在制备预防和治疗肝纤维化与肝硬化的药物中的用途
US20040101902A1 (en) Inhibition of Egr-1 expression by ppar-gamma agonists and related compositions and methods
CA3099128C (en) Alterations in endothelin receptors following hemorrhage and resuscitation by centhaquin
Abdallah New trends in pharmacological treatment of acute kidney injury
AU2017249459A1 (en) Treatment of renal cell carcinoma with lenvatinib and everolimus
JP2022516611A (ja) 線維性疾患の治療のための抗エフリン－ｂ２遮断抗体
CN110604735B (zh) 一种治疗肝纤维化、硬皮病的化合物及其应用
AU2015203036A1 (en) Methods of Treating Hepatorenal Syndrom and Hepatic Encephalopathy with Thromboxane-A2 Receptor Antagonists
TW202434232A (zh) 化合物1在治療或預防腎纖維化等疾病中的應用
Ge et al. IMB16-5 alleviates liver fibrosis by targeting MICALL2/β-catenin signaling
CN115245509A (zh) 一种3-苯基戊二酸衍生物小分子在制备防治缺血再灌注导致的慢性肾脏病药物中的应用
Tang et al. Department of Nephrology and Transplantation, Guy's, King's College and St Thomas' Hospitals Medical School, King's College London, 2Department of Medicine, University of Hong Kong, Queen Mary Hospital Sydney Tang, Joseph CK Leung1. 2, Loretta YY Chan, Anita WL Tsang2, Catherine X. R Chen2, Wuding Zhou1, Kar-Neng Lai2, Steven H.
Zarjou et al. VEGFR3 tyrosine kinase inhibition aggravates cisplatin nephrotoxicity
Friedman et al. Proceedings of the American Society of Pediatric Nephrology 1994 Educational Symposium, Seattle, WA., 1, 2 May, 1994
Iglesias et al. THYROID DYSFUNCTION AND KIDNEY DISEASE (Revised version)

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination